Member Info for Vertizea-Sun

The past is a foreign country, they do things differently there etc, etc

Wrong. The LFT never got close to a patient/recipient.

AVA6000 is in 150 humans. And is working.

Side effects so horrendous it can't be used on pensioners or anyone with heart problems. In fact, on anybody who isn't as strong as an ox.

I've always thought that March 2025 will be pivotal and I still do. A little bit of patience required.

Remember...pre|CISION® is risk-off.

It's worked in the first 59 patients and however many in Phase1B (up to 90)...not a single failure.

Rival companies have spent decades trying to target the tumour and only Avacta can prove a working compound. That alone is priceless.

I couldn't be bothered with the imbecile.

"because Avacta were able to combine this powerful well-known chemotherapy medication with an engineered peptide (PDC – peptide drug conjugate) which is able only to target the cancer environment where there is FAP, and so make this medication even more powerful."

"Because of this new technology do you, an ONCOLOGIST but also a SURGEON, now have to operate on fewer patients?"

You're a fool.

https://www.alainelkanninterviews.com/virgilio-sacchini-4/

Whereas one of the US's leading oncologists/breast surgeon (named and putting his reputation on the line) says of pre|CISION/AVA6000:

"It is like having a rocket with a nuclear bomb inside, and the rocket is directed right away to the cancer cells – not to the body, because it would destroy the body, but to the cancer cells – and therefore able to spare the other parts of the body. Avacta has an incredible technology,"

But what does he know compared to Thorn/eggy/NDN?

Ancient web site

Hit middle button on top line and look for "English"

Does it matter. They knew enough to try and tell the world via one little article. It was an insane interview. Thirteen times Avacta was mentioned.

"It is interesting in that gene editing is a potential treatment for some cancers."

Indeed.

I'm not qualified to judge but what exactly are these people doing with Affimers?

http://www.affyxell.com/en/

The AFX platform technology is based on Daewoong’s mesenchymal stem cell platform (DW-MSC) that has overcome current limitation of tissue-derived mesenchymal stem cell, and Affimer platform technology has been adapted to improve immunomodulation.

"I just don't understand any positive reason for ambiguity or any opaqueness"

There isn't any, except in your mind. See a doctor....soon.

You people must have a pretty low opinion of US doctors if you think cancer patients will be kept waiting for weeks. Jesus.F.Christ. What goes through your minds?

"So the drug (Doxorubicin) is not new, but the engineering is new, because Avacta were able to combine this powerful well-known chemotherapy medication with an engineered peptide (PDC – peptide drug conjugate) which is able only to target the cancer environment where there is FAP, and so make this medication even more powerful"

https://www.alainelkanninterviews.com/virgilio-sacchini-4/

I never thought DX would be sold quickly and this is the third or fourth time I've mentioned it.

TRYING TO SELL A COMPANY TWICE IN A COUPLE OF YEARS IS NOT A GOOD IDEA. And with knobs on if Germany is involved.

From Wyndrum......"success or failure, (there is no middle ground)"

pre|CISION® to cleave from FAP has been administered to more than 100 patients without a single failure. How much is that worth today, if it was offered on the open market?

I'll say again....how much would Novartis or anyone from Big Pharma pay if the IP and patents were offered, straight over the table?????

Engaging with Tempus tells me Avacta intend remaining independent and no T/O planned:

1......Announce Phase 1B data.

2......Then inform on first license deal and cash received.

3...... NASDAQ later in 2025.

Free advice to traders....beware the Ides of March.

"expecting news today if being honest"

You may get lucky later this week but last summer's mind set of "judge us in six months" seems to have been set aside. Perhaps Shaun Chilton thought of it as just a figure of speech. Data from Phase 1B is probably not seeing the light of day for another four weeks...at the earliest. We don't even know if the patients are on the two or three week cycle.....unless I've missed the announcement.

The new financial year, beginning April, is just around the corner and that might now be a factor for all interested parties.

We grind on.

From 2018.

It took at least fifteen years for horses to be replaced by fuel engines so I could argue we are halfway.